The DOJ has charged generic drug giant Glenmark Pharmaceuticals with manipulating the prices of drugs sold in the U.S., as part of a broad federal probe of price-fixing in the generics industry
The Justice Department on Tuesday charged generic drug giant Glenmark Pharmaceuticals with manipulating the prices of drugs sold in the U.S., as part of a broad federal probe of price-fixing in the generics industry.
The charging document alleges that Glenmark and other pharmaceutical companies conspired to raise the price of the cholesterol drug pravastatin. It names Apotex as one of the companies with which Glenmark allegedly conspired. “By cheating through fixing prices, generic drug companies artificially raised prices even though prescription drug costs were already sky high,” Makan Delrahim, who heads DOJ’s Antitrust Division, said in a statement. “As today’s charge shows, the Antitrust Division will not hesitate to charge these companies, and litigate where necessary, particularly where their crimes resulted in hundreds of millions of dollars in overcharges for life-saving medications.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Japan's Takeda expects $200 million operating loss related to Novartis' Xiidra withdrawalTakeda Pharmaceutical Co Ltd said on Monday it anticipates an operating loss of about $200 million related to Novartis AG's decision to withdraw a marketing application for the dry-eye drug Xiidra.
Read more »
Democrats Are on Pace for a Down-Ballot BlowoutThe party’s lead in the congressional generic ballot is higher now than it was in 2018.
Read more »
Gilead prices COVID-19 drug candidate remdesivir at $2,340 per patient in U.S.Gilead Sciences Inc has priced its COVID-19 drug candidate remdesivir at $390 per vial for the United States and governments of other developed countries, it said on Monday, setting the price of a five-day course at $2,340 per patient.
Read more »
Gilead prices COVID-19 drug candidate remdesivir at $2,340 per patientThe price tag is below the $5,080 per course recommendation by U.S. drug pricing research group, the Institute for Clinical and Economic Review (ICER), last week. Remdesivir is at the forefront of the fight against COVID-19 after the anti-viral treatment helped shorten hospital recovery times in a clinical
Read more »
Gilead prices coronavirus drug remdesivir at $2,340 for five-day treatmentGilead says it will charge the U.S. government and other developed countries $2,340 for a typical course of remdesivir. The price will then rise.
Read more »
Gilead prices COVID-19 drug remdesivir at $2,340 per patient in developed nationsGilead Sciences Inc on Monday priced its COVID-19 antiviral remdesivir at $2,340 per patient for wealthier nations and agreed to send nearly all of its supply of the drug to the United States over the next three months.
Read more »